Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
17,410,719
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
110,683
-
Shares change
-
+33,921
-
Total reported value, excl. options
-
$128,503
-
Value change
-
+$41,982
-
Number of buys
-
4
-
Number of sells
-
-3
-
Price
-
$1.16
Significant Holders of ABVC BIOPHARMA, INC. - Common Stock, par value $0.001 per share (ABVC) as of Q4 2023
9 filings reported holding ABVC - ABVC BIOPHARMA, INC. - Common Stock, par value $0.001 per share as of Q4 2023.
ABVC BIOPHARMA, INC. - Common Stock, par value $0.001 per share (ABVC) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 110,683 shares
of 17,410,719 outstanding shares and own 0.64% of the company stock.
Largest 9 shareholders include RENAISSANCE TECHNOLOGIES LLC (36,100 shares), VANGUARD GROUP INC (27,247 shares), CITADEL ADVISORS LLC (27,158 shares), GEODE CAPITAL MANAGEMENT, LLC (19,480 shares), Tower Research Capital LLC (TRC) (578 shares), Spotlight Asset Group, Inc. (100 shares), WELLS FARGO & COMPANY/MN (20 shares), JPMORGAN CHASE & CO (0 shares), and Virtu Financial LLC (0 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.